| Literature DB >> 33238079 |
Karen E Schifferdecker1,2, Rebecca L Butcher1,2, Erin Knight1,2, Emily Creek3, M Suzanne Schrandt3, Laura Marrow3, Marie Jaffe3, Arlene Vinci3, Guy Eakin3.
Abstract
OBJECTIVE: Patient-reported outcome measures (PROMs) are increasingly used in clinical settings but may not provide benefits to patients outside of health encounters. The Arthritis Foundation's Live Yes! Network provides an opportunity for PROM use by individuals and the network that assists individuals with managing their arthritis between encounters. Our objective was to develop a patient-reported outcomes platform for the network, Live Yes! INSIGHTS, using mixed methods and extensive stakeholder input.Entities:
Year: 2020 PMID: 33238079 PMCID: PMC7738808 DOI: 10.1002/acr2.11203
Source DB: PubMed Journal: ACR Open Rheumatol ISSN: 2578-5745
Figure 1Project timeline and data collection methods
Literature review parameters examined and rated for each PROM
|
|
| Participants: was the measure used with a general population, or has it been validated with patients with specific diseases, especially rheumatic diseases? How many participants were included in the stud(ies)? |
| Methods: how was the study carried out? |
| Development of items: what steps were included in the development of the items? The gold standard might include literature review; a panel, interviews, or focus groups with both experts and patients; revision of the measure; pilot testing (eg, content validity) |
|
|
| Frequency of Administration: how much time was in between administrations, both for test‐retest purposes and for responsiveness to change purposes? |
| Time to Complete: did the article(s) include an estimate of how long it takes to complete the measure, either as a whole or by subscale? If so, how long? |
|
|
| Measurement Properties: were key psychometrics evaluated (eg, reliability and validity), and if so, how should they be interpreted? |
| Items: how many items are included in the measure? If the measure has subscales, what are the subscales? What is the response scale? |
|
|
| Registries in use: is the measure included on a well‐known registry (ie, RISE, PR‐COIN, VARA)? Was it previously reviewed in a literature review? |
| Associated Fees: what is the fee for using the measure and permissions required? |
NGT and focus group participant demographics
| Response |
NGT number (%) |
Focus group number (%) | |
|---|---|---|---|
| Gender | Female | 17 (77%) | 49 (89%) |
| Male | 5 (23%) | 6 (11%) | |
| n | 22 | 55 | |
| Age | Average age (and range) |
57 years (38‐75) |
62 years (25‐85) |
| Average age of dependent (and range, n = 8) | ‐ |
15 years (10‐19) | |
| n | 20 | 56 | |
| Race | |||
| (multiple answers allowed) | White | 20 (95%) | 35 (64%) |
| Hispanic or Latino | ‐ | 1 (2%) | |
| Black or African American | 1 (5%) | 22 (40%) | |
| American Indian or Alaska Native | ‐ | 1 (2%) | |
| Asian | ‐ | ‐ | |
| Middle Eastern or North African | ‐ | ‐ | |
| Native Hawaiian or Pacific Islander | ‐ | ‐ | |
| n | 21 | 55 | |
| Highest education | Less than high school | ‐ | 1 (2%) |
| High school diploma/GED | ‐ | 5 (9%) | |
| Some college (including AA or technical degree) | 3 (14%) | 19 (36%) | |
| 4‐year college degree | 7 (33%) | 14 (26%) | |
| Graduate degree (eg, Masters, Doctorate) | 11 (52%) | 14 (26%) | |
| n | 21 | 53 | |
|
Role (multiple answers allowed) | Patient with a rhematic disease | 18 (86%) | 48 (81%) |
| Caregiver to a person with a rheumatic disease | 1 (5%) | 11 (19%) | |
| Measurement expert | |||
| 2 (9%) | ‐ | ||
| Health care provider | 1 (5%) | ‐ | |
| Other | 0 | 7 (12%) | |
| n | 22 | 59 | |
|
Diagnosis (self‐reported or caregiver reported; checked all that applied) | Ankylosing spondylitis | 2 (9%) | 4 (7%) |
| Fibromyalgia | 2 (9%) | 5 (9%) | |
| Gout | 2 (9%) | 9 (16%) | |
| Juvenile rheumatoid arthritis | 0 | 7 (13%) | |
| Lupus | 2 (9%) | 6 (11%) | |
| Osteoarthritis | 12 (55%) | 31 (55%) | |
| Psoriatic arthritis | 2 (9%) | 2 (4%) | |
| Rheumatoid arthritis | 6 (27%) | 19 (34%) | |
| Other (eg, juvenile idiopathic arthritis, viral arthritis) | 1 (5%) | 10 (18%) | |
| n | 22 | 56 | |
| Disease duration | <1 year | 0 | 4 (7%) |
| 1‐4 years | 2 (9%) | 19 (34%) | |
| 5‐10 years | 4 (18%) | 6 (11%) | |
| >10 years | 13 (59%) | 27 (48%) | |
| n | 22 | 56 |
A few participants did not respond to a few or all demographic questions.
Key triangulated themes across methods
| Results | Interviews | NGTs | Focus groups |
|---|---|---|---|
| Usefulness of INSIGHTS | |||
| Support for Foundation to implement INSIGHTS longitudinally and the three domains | X | X | |
| INSIGHTS results can be used for multiple purposes by patients, Foundation, external stakeholders | X | X | X |
| Considerations for implementation | |||
| Ensure and message value and relevance to patients | X | X | X |
| Vary frequency of data collection per domain to reduce burden | X | X | X |
| Communicate clear purpose and pathway for participating | X | X | |
| Include demographics, medication, lifestyle changes to interpret findings and assist in future research | X | X | X |
| Choose items that are clear and applicable to ensure accuracy and quality of data | X | X | |
| Concerns | |||
| Concerns about data privacy and security | X | X | |
| Mixed feelings about comparing individual results to group results | X | X |